Kewalramani Reshma's Form 4/A amendment
AmendedVertex Pharmaceuticals Inc (VRTX) · filed Jul 21, 2022
- Accession no.
- 0000899243-22-026481
- Filed
- Jul 21, 2022
- Rule 10b5-1 plan
- Not on the form (before 2023)
- Original filed
- Jun 28, 2022
This filing lists no transactions. It carries over 1 transaction from the original filing that it did not restate. Open-market sales total $3.41M.
This amendment restates part of 0000899243-22-024385 (filed Jun 28, 2022). The transactions it did not restate still count and are listed below.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Kewalramani ReshmaCIK 0001735944 | Director, Officer (CEO & President) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
This filing has no transactions of this kind.
Carried over from the original filing
This amendment restates only part of the original filing. The original's other transactions still stand, and the trade tables on Livermore count them under this amendment.
From 0000899243-22-024385 (filed Jun 28, 2022).
Non-derivative securities (Table I)
Footnotes on the original
The footnotes that the prices of these transactions refer to on the original filing.
- F2
Dr. Kewalramani undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
Referenced by the price of 1 transaction in Table I.
- F3
Open market sales reported on this line occurred at a weighted average price of $291.30 (range $291.00 to $291.49).
Referenced by the price of 1 transaction in Table I.
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
The Form 4 filed by Dr. Kewalramani on June 28, 2022 inadvertently excluded 134 shares acquired by Dr. Kewalramani under the issuer's Employee Stock Purchase Plan. This amendment reports all of the shares beneficially owned by Dr. Kewalramani following the transactions reported on the original Form 4.